These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31602769)

  • 1. Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre.
    Wheeler M; Borrie A; Dookia R; Carter J
    Intern Med J; 2019 Oct; 49(10):1316-1320. PubMed ID: 31602769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
    Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Experience with Idarucizumab to Reverse Anticoagulant Effect in Dabigatran-Treated Patients: Report of 11 Cases from Taiwan.
    Tsai LK; Lin HJ; Chua SK; Liao PC; Yang YP; Chou PC; Lee CW; Lin MJ; Chen HM; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):e27-e33. PubMed ID: 29122465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
    Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran Reversal with Idarucizumab in an Emergency Lumbar Puncture: A Case Report.
    Spagnolello O; Letteri F; Falcou A; Cipollone L; De Michele M; Bertazzoni G; Toni D
    Curr Drug Saf; 2019; 14(1):40-42. PubMed ID: 30112997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarucizumab: First Global Approval.
    Burness CB
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran.
    Giannandrea D; Mengoni A; Carluccio E; Ambrosio G
    Vasc Health Risk Manag; 2019; 15():139-142. PubMed ID: 31213821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
    Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
    Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab: The Antidote for Reversal of Dabigatran.
    Eikelboom JW; Quinlan DJ; van Ryn J; Weitz JI
    Circulation; 2015 Dec; 132(25):2412-22. PubMed ID: 26700008
    [No Abstract]   [Full Text] [Related]  

  • 20. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.